Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer
Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference
Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities
Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent
